Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSPro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's DiseasePlatelet biomarkers in Alzheimer's diseaseCerebrospinal fluid and blood biomarkers in Alzheimer's diseaseMild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's diseaseCalpastatin modulates APP processing in the brains of β-amyloid depositing but not wild-type miceBiana: a software framework for compiling biological interactions and analyzing networks.Targeting protein kinases in central nervous system disordersSilencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice.Blood-based biomarkers of Alzheimer's disease: challenging but feasibleMultiple alternative splicing and differential expression pattern of the glycogen synthase kinase-3β (GSK3β) gene in goat (Capra hircus)Identifying and validating biomarkers for Alzheimer's disease.Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3β, neurotrophin-3 and CREB signaling.Glycogen-synthase kinase-3beta is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairmentMorin attenuates tau hyperphosphorylation by inhibiting GSK3β.Altered regulation of tau phosphorylation in a mouse model of down syndrome agingBiomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.The GSK3 hypothesis of Alzheimer's diseaseProteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodiumAlzheimer's Disease, Diagnosis and the Need for Biomarkers.Chipping away at diagnostics for neurodegenerative diseasesModulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies.GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration.Biomarkers in Sporadic and Familial Alzheimer's Disease.Glycogen synthase kinase-3β regulates leucine-309 demethylation of protein phosphatase-2A via PPMT1 and PME-1.Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?Gsk3β aggravates the depression symptoms in chronic stress mouse model.Synthesis and preliminary characterization of radioiodinated benzofuran-3-yl-(indol-3-yl)maleimide derivatives as potential SPECT imaging probes for the detection of glycogen synthase kinase-3β (GSK-3β) in the brain.Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment?The peripheral messenger RNA expression of glycogen synthase kinase-3β genes in Alzheimer's disease patients: a preliminary study.Biomarker identification for diagnosis of Alzheimer's disease.Glycogen synthase kinase-3β regulates Tyr307 phosphorylation of protein phosphatase-2A via protein tyrosine phosphatase 1B but not Src.Global Approaches to Understanding Protein Kinase Functions
P2860
Q21129334-35FD0F32-837A-4138-B788-A218E6D33113Q26795492-AA620950-B969-414D-B88A-B13F0751D351Q26858851-3F04757E-245D-4B9C-8E30-766B5ACC4D5EQ27023758-D56D6091-2873-4D9B-863B-DE825D438DC5Q27027319-CB841564-79E5-46A1-98E6-1A755092E014Q30454134-F6980011-A235-401C-99B8-2F5284516223Q33526856-17CF98E5-00CB-4903-9849-A6A5FE6E8D29Q33671660-941EC28D-E772-481A-882E-4DA4553E7495Q33766526-A5786366-E63B-482F-8967-D3AE8D4F9726Q33824444-8EC7E9A2-5B4A-4F10-BB63-D3D9D6E6645BQ34343577-A400E4C7-31F9-4305-A0D4-6E00FC2153C7Q34468961-FCC7A44C-FF3A-4EE6-A33E-8D56F5DC4CD0Q34735544-421BF966-67BD-443B-9E86-433F04C3B667Q35028865-C5E98145-CDC4-4B26-A4E9-B427A65BCE0CQ35196301-12442EFB-A37B-4D24-A156-918774D6B554Q35859514-9281DBE7-3376-4E02-A2FC-F83525047933Q36754193-6FA8D69A-D800-40E5-9CB5-35446CA7CDC4Q37035378-15736C41-C148-4AFA-B0F3-6201EFF80C9FQ37052151-82E6787C-E801-4E61-A628-F63EC20D31D6Q37207324-F92892F1-E57F-46C5-B126-1D21DF060424Q37366183-6F2F42E2-7F6A-4146-91F8-B60DEB194BA4Q37946881-161C4AC9-1A26-448D-98F2-8C7A03DEAD33Q37959957-5524AD32-2540-4C4C-A0AF-F8E18C87D6E2Q38592041-128B0431-B2CC-4B63-8B40-E8CCA27DD718Q39325433-04849A98-66EA-4F5A-92B0-91AFD92A7E82Q39728463-381711A1-BB1C-41BB-B7CD-D26AC2964312Q45288661-0B92B37A-A22F-49E4-8CDF-4464CB295DD9Q47161596-E6ED1568-447B-437B-84CC-12D0D9AE0AFBQ47737589-5D4923B1-CB3A-4BBA-AEB3-5796D42A11EAQ48786282-8CE66B4F-85BB-4246-860E-CAFA8C80F1EEQ48912689-68D26C1B-3510-4814-A411-627560185573Q50729633-07AC07D7-76BD-4442-9E38-E8DD414DA8A7Q53480286-C69BDBC1-1377-4037-BF8D-789C65FE8540Q54591455-073E522D-067C-4C7B-A629-AD2F63766E45Q57833109-7864B329-5E94-4A11-A04F-95CFA2EE2F5F
P2860
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
@en
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
@nl
type
label
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
@en
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
@nl
prefLabel
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
@en
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
@nl
P2093
P50
P1433
P1476
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
@en
P2093
Brian Anderton
Catherine Foy
Gillian Hamilton
John Powell
Michaela Poppe
Nicola Archer
P356
10.1016/J.NEULET.2004.10.031
P407
P577
2005-01-01T00:00:00Z